The most oversold stocks in the health care sector present an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Don’t Miss Out:
- A billion-dollar investment strategy with minimums as low as $10 — you can become part of the next big real estate boom today.
This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing. - Interest rate cuts could supercharge the real estate industry. Get started investing in commercial real estate today.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
Progyny Inc PGNY
- On Sept. 19, the company said a client elected to exercise an option to terminate its services agreement with the company. The company's stock fell around 32% over the past five days and has a 52-week low of $13.93.
- RSI Value: 26.50
- PGNY Price Action: Shares of Progyny rose 1% to close at $16.62 on Friday.
- Benzinga Pro's real-time newsfeed alerted to latest PGNY news.
Indivior PLC INDV
- On Sept. 4, Indivior issued an update on Aelis Farma’s Phase 2B study with AEF0117 in participants with cannabis use disorder. It has a 52-week low of $9.14.
- RSI Value: 25.92
- RELI Price Action: Shares of Indivior fell 2.1% to close at $9.48 on Friday.
- Benzinga Pro’s charting tool helped identify the trend in INDV stock.
Check It Out: This billion-dollar fund has invested in the next big real estate boom, here's how you can join for $10.
This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.
Moderna Inc MRNA
- On Sept. 17, Moderna announced that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.The vaccine targets the KP.2 variant of COVID-19. The company plans to begin delivery of the vaccine to the Public Health Agency of Canada shortly. "With the recent increase in COVID-19-infections, staying up to date with your COVID-19 vaccination remains one of the best ways to help protect yourself from severe illness," said Dr. Shehzad Iqbal, country medical director, Moderna Canada. The company's shares fell around 20% over the past month and has a 52-week low of $62.55.
- RSI Value: 28.17
- MRNA Price Action: Shares of Moderna fell 3.4% to close at $65.69 on Friday.
- Benzinga Pro’s signals feature notified of a potential breakout in MRNA shares.
Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Keep Reading:
- This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, and you only need $100.
- What is private credit exactly? Find out more about the alternative asset with double-digit potential returns – that's outperformed equities and high yield bonds in the last 3 market downturns.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.